Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: InMed is a pharmaceutical company developing proprietary small molecule drug candidates targeting the endocannabinoid system (CB1 and CB2 receptors) for diseases with high unmet medical needs. The company operates two segments: InMed Pharma (drug development) and BayMedica Commercial (B2B sales of bulk rare cannabinoids for the health and wellness sector).
Key Pipeline Assets:
- INM-901: Alzheimer's disease (preclinical).
- INM-089: Dry Age-Related Macular Degeneration (preclinical).
- INM-755: Epidermolysis Bullosa (Phase 2 completed; seeking partners).
Key Financial Metrics
| Metric (in thousands) | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Total Revenue | $4,943 | $4,598 |
| Gross Profit | $1,707 | $1,101 |
| Gross Margin | 34.5% | 23.9% |
| Net Loss | $(8,162) | $(7,676) |
| Operating Cash Flow | $(7,767) | $(6,986) |
| Cash & Equivalents (End of Period) | $11,076 | $6,572 |
| Accumulated Deficit | $(117,238) | $(109,076) |
Note: Revenue is derived entirely from the BayMedica segment. The InMed Pharma segment generated no revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8% to $4.9 million, driven by expanded marketing and demand for rare cannabinoids in the BayMedica segment.
- Margin Expansion: Gross margin improved significantly from 24% to 35% due to reduced supply chain costs and lower inventory write-downs.
- Net Loss Increase: Net loss widened by approximately 6% ($0.5 million) primarily due to increased General and Administrative (G&A) expenses and new finance expenses related to the Standby Equity Purchase Agreement (SEPA).
- Financing Activity: The company raised approximately $13.2 million in gross proceeds during the fiscal year through a Private Placement ($5.0 million), SEPA issuances ($6.2 million), and an At-The-Market (ATM) offering ($1.9 million).
- Reverse Stock Split: A 20-for-1 reverse stock split was effected in November 2024 to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, Risks, and Contingencies
Outlook and Liquidity:
- Management estimates current cash reserves ($11.1 million) will fund operations into the fourth quarter of calendar 2026, contingent on BayMedica revenue realization and expense management.
- The company has concluded there is substantial doubt about its ability to continue as a going concern within one year of the report issuance date due to recurring losses and the need for additional capital.
- Future funding will likely require equity financings, debt, or strategic partnerships.
- INM-901: Recent preclinical data demonstrated significant reduction in neuroinflammation markers in ex vivo models, supporting its potential for Alzheimer's treatment.
- INM-755: Phase 2 results showed positive indications for anti-itch activity in Epidermolysis Bullosa; the company is actively seeking commercial partners as it has deprioritized internal advancement of this program.
- Legal Proceedings: BayMedica is involved in an arbitration matter ("Patent License Matter") with a third-party licensor. The licensor seeks approximately $3.4 million in past payments and $2.3 million annually for the remainder of the agreement term. BayMedica disputes these claims, but an unfavorable outcome could materially impact operations.
- Regulatory: Product candidates are in early stages with a high probability of failure. No products have received FDA approval.
- Market Risk: The company recently regained Nasdaq compliance via a reverse split but faces ongoing risks regarding minimum bid price maintenance.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing before Q4 2026 to avoid liquidity crises.
- Arbitration Outcome: Monitor the status of the "Patent License Matter" involving BayMedica, as a loss could result in significant cash outflows ($5.7M+).
- Partnership Progress: Assess the timeline for securing a commercial partner for INM-755, as internal development is paused.
- Capital Dilution: Review the terms of the SEPA and recent Private Placement, noting the issuance of pre-funded warrants and preferred investment options that may lead to future dilution.
- Revenue Concentration: Note that 100% of revenue comes from BayMedica; verify customer concentration risks (two customers accounted for 58% of revenue in 2025).